Valneva Preliminary 2024 Revenue €169.6M (+10% YoY), Product Sales Hit €163.3M (+13% YoY); Cash And Cash equivalents €168.3M

Benzinga

02-18

Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023)
Strong year-end cash position of €168.3 million
Substantial clinical and regulatory progress in 2024, leading to multiple anticipated data readouts, product approvals and label extensions in 2025
2025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&D investments with lower operating cash burn

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2512840731"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2512840731\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2512840731?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-18 14:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2512840731","market":"us","top_or_hot":-1,"title":"Valneva Preliminary 2024 Revenue €169.6M (+10% YoY), Product Sales Hit €163.3M (+13% YoY); Cash And Cash equivalents €168.3M","media":"Benzinga","content":"<html><body><ul><li>Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023)</li><li>Strong year-end cash position of €168.3 million</li><li>Substantial clinical and regulatory progress in 2024, leading to multiple anticipated data readouts, product approvals and label extensions in 2025</li><li>2025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&amp;D investments with lower operating cash burn</li></ul></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Valneva Preliminary 2024 Revenue €169.6M (+10% YoY), Product Sales Hit €163.3M (+13% YoY); Cash And Cash equivalents €168.3M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nValneva Preliminary 2024 Revenue €169.6M (+10% YoY), Product Sales Hit €163.3M (+13% YoY); Cash And Cash equivalents €168.3M\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2025-02-18 14:45</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<html><body><ul><li>Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023)</li><li>Strong year-end cash position of €168.3 million</li><li>Substantial clinical and regulatory progress in 2024, leading to multiple anticipated data readouts, product approvals and label extensions in 2025</li><li>2025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&amp;D investments with lower operating cash burn</li></ul></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VALN","symbol_name":"Valneva SE","start_time":0,"source_url":"https://www.benzinga.com/news/earnings/25/02/43773005/valneva-preliminary-2024-revenue-169-6m-10-yoy-product-sales-hit-163-3m-13-yoy-cash-and-cash-equiva","article_id":"2512840731","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2512840731","pubTimestamp":1739861112,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023)Strong year-end cash position of €168.3 millionSubstantial clinical and regulatory progress in 2024, leading to multiple","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"VALN":"Valneva SE"},"translate_title":"Valneva 2024年初步收入为1.696亿欧元（同比增长10%），产品销售额达到1.633亿欧元（同比增长13%）；现金及现金等价物1.683亿欧元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VALN":0.9},"content_text":"Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023)Strong year-end cash position of €168.3 millionSubstantial clinical and regulatory progress in 2024, leading to multiple anticipated data readouts, product approvals and label extensions in 20252025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&D investments with lower operating cash burn","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}